Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate ...

Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide ...

In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high ...

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.

Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.

Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.

Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.

Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy ...

Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and ...

The Community Oncology Alliance said CMS’s final 2027 outpatient rule pays 340B hospitals ASP minus 28% for drugs, but ...

In DAREON-7, first-line obrixtamig plus chemo yielded responses across DLL3 expression levels in epNEC, with the most durable ...

In the CABINET trial, cabozantinib extended PFS vs placebo in advanced NETs regardless of hormone functional status, with ...